Research and Clinical Trials
Advances in breast cancer prevention have resulted in new and innovative opportunities to modify breast cancer risk.
Researchers have learned you don't need a family history of colorectal cancer to have a genetic mutation that predisposes you to the disease.
A study is validating the use of genomic sequencing to predict the likelihood that patients with gastric cancer will derive benefit from therapies.
Research on adagrasib has demonstrated promising clinical activity in patients with gastrointestinal cancers that harbor KRAS G12C mutations.
Findings from a recent Mayo Clinic study suggest that knowledge of skin cancer risk could influence risky behavior, such as tanning bed use.
Mayo Clinic researchers may have discovered a genomic signature to predict which people with mesothelioma could benefit from immunotherapy.
A Mayo Clinic study bolsters evidence that colorectal cancer is often imprinted in family genes and passed on from one generation to the next.
Folakemi Odedina, Ph.D., a Mayo Clinic cancer researcher and global health equity expert, explains why closing the care gap in cancer care is good for everyone.
A microbe in the uterine microbiome could be a contributing driver of endometrial cancer, according to a Mayo Clinic study.
The new executive director of Mayo Clinic Cancer Programs and director of Mayo Clinic Cancer Center, Dr. Cheryl Willman, shares her thoughts on how to reach all those in need of cancer care.